

## Special Issue

# Advances in Antileishmania Drug Agent

### Message from the Guest Editor

Leishmaniasis is a spectrum of infectious and parasitic diseases caused by protozoa of the genus *Leishmania*. Given the groups of people it affects (usually low-income) and the lack of investment in chemotherapy treatment research, Leishmaniasis is considered a Neglected Tropical Disease (NTD). Treatment of leishmaniasis by chemotherapy remains a challenge because of limited efficacy, toxic side effects, and drug resistance. The search for new therapeutic agents from natural sources has been a constant for the treatment of diseases such as leishmaniasis. This Special Issue on *Pharmaceutics* aims to gather relevant manuscripts involving basic, translational, and clinical research, and covering various advances in treatment for leishmaniasis. For this research topic, we are inviting interested researchers to share their original research, relevant findings, and review articles in the areas of antileishmanial drug identification, drug combinations, immunotherapy, drug delivery systems, parasite drug resistance; and target identification and validation for tropical protozoan diseases of medical interest.

### Guest Editor

Prof. Dr. Klinger Antonio Da Franca Rodrigues

Infectious Disease Laboratory—LADIC, Federal University of Parnaíba Delta—UFDPAr, Campus Ministro Reis Velloso, São Benedito, Parnaíba 64202-020, Brazil

### Deadline for manuscript submissions

closed (10 February 2025)



## Pharmaceutics

an Open Access Journal  
by MDPI

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/204857](https://mdpi.com/si/204857)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).